Study of Brain Changes Shaped by Experience
Healthy, Neurologic Manifestations
About this trial
This is an observational trial for Healthy focused on measuring Plasticity, Motor, Stroke, Amphetamine, fMRI, Cortical Reorganization, Spectroscopy
Eligibility Criteria
Patients must be able to give informed consent. Patients recruited would come from those referred to the Human Cortical Physiology Section who would have distinct neurological syndromes from well-defined peripheral and central nervous system lesions including stroke, hemipherectomy, and amputation. Healthy adults without history of neurological disease. Pregnant women will be excluded. Subjects with metal in the cranium except mouth will be excluded. Subjects with dental braces will be excluded. Subjects with metal fragments from occupational exposure or surgical clips in or near the brain will be excluded. Subjects with eye, blood vessel, cochlear or eye implants will be excluded. Subjects with increased intracranial pressure as evaluated by clinical means will be excluded. Subjects with cardiac or neural pacemakers will be excluded. Subjects with intracardiac lines and implanted medication pumps will be excluded. ADDITIONAL INCLUSION CRITERIA WHEN AMPHETAMINE IS USED: Subjects with large hemorrhagic or brain stem stroke will be excluded. Subjects with multiple cerebral lesions with residual deficits will be excluded. Subjects with history of head injury with loss of consciousness will be excluded. Subjects with history of severe alcohol or drug abuse will be excluded. Subjects with history of psychiatric illness will be excluded. Subjects with unstable cardiac dysrhythmia or unresponsive arterial hypertension (greater than 160/100 mmHg) will be excluded. Subjects with history of hyperthyroidism will be excluded. Subjects receiving alpha-adrenergic antagonists or agonist, major/minor tranquilizers, clonidine, prazosin, phenytoin, benzodiazepines, scopolamine, haloperidol, other neuroleptics, barbiturates will be excluded. Subjects with glaucoma, history of hypersensitivity or idiosyncrasy to sympatomimetic drugs will be excluded.
Sites / Locations
- National Institute of Neurological Disorders and Stroke (NINDS)